- Home
- CRVO vs GALT Comparison
CRVO vs GALT Comparison
Compare CRVO & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVO
- GALT
- Stock Information
- Founded
- CRVO 2001
- GALT 2000
- Country
- CRVO United States
- GALT United States
- Employees
- CRVO N/A
- GALT N/A
- Industry
- CRVO Biotechnology: Pharmaceutical Preparations
- GALT Biotechnology: Pharmaceutical Preparations
- Sector
- CRVO Health Care
- GALT Health Care
- Exchange
- CRVO Nasdaq
- GALT Nasdaq
- Market Cap
- CRVO 95.4M
- GALT 86.0M
- IPO Year
- CRVO N/A
- GALT N/A
- Fundamental
- Price
- CRVO $8.49
- GALT $1.38
- Analyst Decision
- CRVO Strong Buy
- GALT Hold
- Analyst Count
- CRVO 8
- GALT 1
- Target Price
- CRVO $25.43
- GALT N/A
- AVG Volume (30 Days)
- CRVO 453.1K
- GALT 173.6K
- Earning Date
- CRVO 05-20-2025
- GALT 05-19-2025
- Dividend Yield
- CRVO N/A
- GALT N/A
- EPS Growth
- CRVO N/A
- GALT N/A
- EPS
- CRVO N/A
- GALT N/A
- Revenue
- CRVO $9,737,974.00
- GALT N/A
- Revenue This Year
- CRVO N/A
- GALT N/A
- Revenue Next Year
- CRVO N/A
- GALT N/A
- P/E Ratio
- CRVO N/A
- GALT N/A
- Revenue Growth
- CRVO 36.29
- GALT N/A
- 52 Week Low
- CRVO $1.80
- GALT $0.73
- 52 Week High
- CRVO $25.69
- GALT $3.41
- Technical
- Relative Strength Index (RSI)
- CRVO 46.29
- GALT 49.81
- Support Level
- CRVO $8.40
- GALT $1.26
- Resistance Level
- CRVO $11.79
- GALT $1.63
- Average True Range (ATR)
- CRVO 0.99
- GALT 0.13
- MACD
- CRVO -0.19
- GALT 0.02
- Stochastic Oscillator
- CRVO 10.45
- GALT 37.50
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.